Danielle Marie Brander
Assistant Professor of Medicine
Current Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2017
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2016
Contact Information
- Dept Of Medicine, Box 3872 DUMC, Durham, NC 27710
-
danielle.brander@duke.edu
(919) 684-8166
- Background
-
Education, Training, & Certifications
- Resident, Internal Medicine, Duke University School of Medicine 2007 - 2010
- M.D., Duke University School of Medicine 2007
-
Duke Appointment History
- Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013 - 2017
- Research
-
Selected Grants
- BGB-3111-304 awarded by BeiGene, Ltd 2018 - 2023
- D15-11094 awarded by Zhejiang DTRM Biopharma Co.Ltd. 2018 - 2023
- UTX-TGR-501 awarded by TG Therapeutics, Inc 2018 - 2023
- DFCI Obinutuzumab and Ibrutinib Protocol # 15-283 awarded by Dana Farber Cancer Institute 2017 - 2022
- Ph 2 Study of TGR-1202 in Patients with CLL awarded by TG Therapeutics, Inc 2016 - 2021
- Multi-Center, Open-Label Study of Ublituximab (TG-1101) in combination with TGR-1202 awarded by TG Therapeutics, Inc 2016 - 2021
- Ph 3 of Ublituximab in Combination with TGR-1202 awarded by TG Therapeutics, Inc 2016 - 2021
- Phase III study of ACP-196 vs Ibrutinib in High Risk CLL awarded by Acerta Pharma 2016 - 2021
- A Phase II Study of Ibrutinib in combo with Fludarabine, Cyclophosphamide and Rituximab for young patients with CLL awarded by Dana Farber Cancer Institute 2015 - 2020
- Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts. awarded by TG Therapeutics, Inc 2015 - 2020
- Gilead GS-US 312 0133 awarded by Gilead Sciences, Inc. 2014 - 2019
- Screening protocol to determine high risk cytogenetic features in previously treated CLL awarded by TG Therapeutics, Inc 2016 - 2017
- A Phase II Study of PNT2258 in Patients with Richter's Transformation (RT). awarded by ProNAi Therapeutics, Inc. 2016 - 2017
- MedImmune CD-ON-CAT-8015-1053 awarded by MedImmune, Inc. 2015 - 2017
- GS-US-312-0123 awarded by Gilead Sciences, Inc. 2014 - 2017
- A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL awarded by Lymphoma Research Foundation of America 2014 - 2016
- Phase 2 GS-US-339-0103 awarded by Gilead Sciences, Inc. 2013 - 2015
- Publications & Artistic Works
-
Selected Publications
-
Journal Articles
- Mato, AR, Samp, JC, Gauthier, G, Terasawa, E, and Brander, DM. "Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies." Cancer Biology & Therapy 19, no. 7 (July 3, 2018): 636-643. Full Text
- Mato, AR, Nabhan, C, Thompson, MC, Lamanna, N, Brander, DM, Hill, B, Howlett, C, Skarbnik, A, Cheson, BD, Zent, C, Pu, J, Kiselev, P, Goy, A, Claxton, D, Isaac, K, Kennard, KH, Timlin, C, Landsburg, D, Winter, A, Nasta, SD, Bachow, SH, Schuster, SJ, Dorsey, C, Svoboda, J, Barr, P, and Ujjani, CS. "Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis." Haematologica 103, no. 5 (May 2018): 874-879. Full Text
- Burris, HA, Flinn, IW, Patel, MR, Fenske, TS, Deng, C, Brander, DM, Gutierrez, M, Essell, JH, Kuhn, JG, Miskin, HP, Sportelli, P, Weiss, MS, Vakkalanka, S, Savona, MR, and O'Connor, OA. "Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study." The Lancet. Oncology 19, no. 4 (April 2018): 486-496. Full Text
- Thompson, M, Brander, D, Nabhan, C, and Mato, A. "Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents." Jama Oncology 4, no. 3 (March 1, 2018): 394-394. Full Text
- Wierda, WG, Byrd, JC, Abramson, JS, Bhat, S, Bociek, G, Brander, D, Brown, J, Chanan-Khan, A, Coutre, SE, Davis, RS, Fletcher, CD, Hill, B, Kahl, BS, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Lancet, J, Ma, S, Malek, S, Mosse, C, Shadman, M, Siddiqi, T, Stephens, D, Wagner, N, Zelenetz, AD, Dwyer, MA, and Sundar, H. "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 11 (November 2017): 1414-1427. Full Text
- Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, A-L, Claxton, DF, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ, and Nabhan, C. "Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients." Annals of Oncology : Official Journal of the European Society for Medical Oncology 28, no. 5 (May 2017): 1050-1056. Full Text
- Brander, DM. "Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?." British journal of haematology 176, no. 3 (February 2017): 337-340. Full Text
- Seymour, JF, Ma, S, Brander, DM, Choi, MY, Barrientos, J, Davids, MS, Anderson, MA, Beaven, AW, Rosen, ST, Tam, CS, Prine, B, Agarwal, SK, Munasinghe, W, Zhu, M, Lash, LL, Desai, M, Cerri, E, Verdugo, M, Kim, SY, Humerickhouse, RA, Gordon, GB, Kipps, TJ, and Roberts, AW. "Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study." The Lancet. Oncology 18, no. 2 (February 2017): 230-240. Full Text
- Strati, P, Lanasa, M, Call, TG, Leis, JF, Brander, DM, LaPlant, BR, Pettinger, AM, Ding, W, Parikh, SA, Hanson, CA, Chanan-Khan, AA, Bowen, DA, Conte, M, Kay, NE, and Shanafelt, TD. "Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial." The Lancet. Haematology 3, no. 9 (September 2016): e407-e414. Full Text
- Friedman, DR, Lanasa, MC, Davis, PH, Allgood, SD, Matta, KM, Brander, DM, Chen, Y, Davis, ED, Volkheimer, AD, Moore, JO, Gockerman, JP, Sportelli, P, and Weinberg, JB. "Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies." Leuk Lymphoma 55, no. 5 (May 2014): 1067-1075. Full Text Link to Item
- Brander, D, Rizzieri, D, Gockerman, J, Diehl, L, Shea, TC, Decastro, C, Moore, JO, and Beaven, A. "Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma." Leukemia & lymphoma 54, no. 12 (December 2013): 2627-2630. Full Text
- Brander, DM, and Beaven, AW. "Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib." Patient preference and adherence 6 (January 2012): 239-251. Full Text
- Bean, GR, Bryson, AD, Pilie, PG, Goldenberg, V, Baker, JC, Ibarra, C, Brander, DMU, Paisie, C, Case, NR, Gauthier, M, Reynolds, PA, Dietze, E, Ostrander, J, Scott, V, Wilke, LG, Yee, L, Kimler, BF, Fabian, CJ, Zalles, CM, Broadwater, G, Tlsty, TD, and Seewaldt, VL. "Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 13, no. 22 Pt 1 (November 2007): 6834-6841. Full Text
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
